Investor News

Investor News

Disseration: A study of Cancer Cells by Digital Holographic Imaging

Sofia Kamlund has studied Cell Division and Cell Movement using Digital Holographic Microscopy. Her research presents new ways of analyzing individual cells by using Holographic Microscopy alone or in combination with Fluorescence Microscopy.

Read more

PHI HoloMonitor User Meeting

PHI had a successful Holomonitor User Meeting where we discussed how to use HoloMonitor with focus on cancer research. The presentations showed new methods within cancer research and cell biology.

Read more

Best Poster Price to Louise Sternbaeck

PHI’s Industrial Doctoral Student Louise Stenbaeck received a price from Danish Cancer Society  for her poster “Holographic microscopy: Macrophage-uptake of SA-MIPs”. Louise’s poster showed something new within cancer research on cell level. Her research within cell proliferation shows that morphological parameters and treatment with the plastic nanoparticles MIP:s (molecularly imprinted polymers) increased the values for cell

Read more

TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression

Cancer kills millions of people every year and is one of humanity’s greatest health challenges. In recent years, immune cells were shown to play critical roles in tumor growth and metastatic progression. The environment where tumor cells live consists of a wide range of cell types, among them immune cells. Even though the power is

Read more

Rights issue enables market expansion

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.

Read more

Digital Holographic Microscopy for biomarker detection in cancer

“In the near future”, Zahra El-Schich says, “you could have a HoloMonitor in every clinic. You could also customize cancer treatment for every patient by just using a simple tumor test.” Find out how.

Read more

Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)

Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.

Read more

New CEO commentary: “Understanding Skin Cancer”

PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.

Read more

Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.

Read more

Fighting cancer at an early stage

Using nanoparticles and HoloMonitor technology Prof. Anette Gjörloff Wingren and her team aim to develop an early screening method that detects cancer by a simple blood test.

Read more